NAD⁺ is an essential co-enzyme that supports cellular energy and metabolic function. As the demand for healthy ageing solutions grows, LNP grade delivery and quality become the difference between simply taking a supplement and building a consistent, premium health programme.
That’s why we created LNP-NAD⁺ as a premium wellness delivery technology:
Scale revenue, not your floor plan.
Move beyond time-and-chair bottlenecks with fast, repeatable dispensing, designed to support stronger retention, predictable recurring revenue, and greater client confidence in your clinic and your brand.
One of the key advantages of LNP-NAD⁺ lies in its ability to deliver a controlled, predictable, and sustained NAD⁺ profile, rather than the abrupt peaks and rapid declines as with the traditional delivery methods such as Liposomal technology.
High dose “bolus” approaches especially IV drips or poorly stabilised oral products can create a brief, supraphysiological surge of circulating NAD⁺ followed by rapid clearance and drop-off. This “spike-and-crash” pattern may leave some patients feeling overwhelmed or nauseous from the sudden surge, with benefits that fade quickly, driving a variable experience and inconsistent results between doses and individuals.
LNP-NAD⁺ is researched to address this challenge at a pharmacokinetic level. By encapsulating NAD⁺ within advanced lipid nanoparticles, the formulation is designed to protect the active molecule, moderate its systemic release, and enhance cellular uptake efficiency. This results in a smoother exposure curve and a more reproducible experience over time, supporting steadier mitochondrial function and cellular energy availability. For patients and clinicians alike, this translates into greater consistency, improved tolerability, and more predictable outcomes, enabling LNP-NAD⁺ to be integrated into structured, repeatable protocols rather than episodic interventions.
Beyond the clinical experience, this consistency also delivers a clear operational and commercial advantage. Predictable effects support protocol standardisation, patient retention, and subscription-based or maintenance programmes, outcomes that are far harder to achieve with variable, peak-dependent therapies. In short, LNP-NAD⁺ shifts NAD⁺ supplementation from an acute, event-driven intervention to a reliable, long-term metabolic support strategy, aligned with both clinical best practice and scalable care models.
For the safe and effective delivery of active agents at the cellular level Lipid Nanoparticle (LNP) represent one of the most significant advances in modern drug delivery and are widely used across the pharmaceutical and biotechnology industries. Their clinical validation in approved medicines and vaccines demonstrates not only their effectiveness, but also their safety, scalability, and regulatory acceptability. LNPs are engineered to protect sensitive active compounds from degradation, improve bioavailability, and facilitate targeted cellular uptake, capabilities that conventional delivery formats such as Liposomal delivery system often fail to achieve.
LNP-NAD⁺ is researched to address this challenge at a pharmacokinetic level. By encapsulating NAD⁺ within advanced lipid nanoparticles, the formulation is designed to protect the active molecule, moderate its systemic release, and enhance cellular uptake efficiency. This results in a smoother exposure curve and a more reproducible experience over time, supporting steadier mitochondrial function and cellular energy availability. For patients and clinicians alike, this translates into greater consistency, improved tolerability, and more predictable outcomes, enabling LNP-NAD⁺ to be integrated into structured, repeatable protocols rather than episodic interventions.
Beyond the clinical experience, this consistency also delivers a clear operational and commercial advantage. Predictable effects support protocol standardisation, patient retention, and subscription-based or maintenance programmes, outcomes that are far harder to achieve with variable, peak-dependent therapies. In short, LNP-NAD⁺ shifts NAD⁺ supplementation from an acute, event-driven intervention to a reliable, long-term metabolic support strategy, aligned with both clinical best practice and scalable care models.
One of the most compelling advantages of LNP-NAD⁺ is the convenience it delivers for both patients and clinics. Traditional IV NAD⁺ therapy often means scheduled appointments, 60–120 minutes of chair time, clinical supervision, and a real disruption to the patient’s day.
LNP-NAD⁺ is designed to support longer, more consistent cellular delivery without infusions, cannulation, or extended in-clinic stays. Patients can integrate NAD⁺ support seamlessly into daily life at home, at work, or even when travelling, while clinics can offer a premium programme that feels effortless, repeatable, and experience-led.
For clinics and providers, this “take-home IV” solutions fundamentally changes service delivery. By removing chair time from the equation, practices can expand access to NAD⁺ programmes beyond the physical limits of treatment rooms and staffing schedules. Patients can be onboarded through brief consultations and supported through structured, repeatable protocols, while clinics benefit from improved efficiency, scalability, and ongoing engagement. The result is a modern, patient-centric model that combines the perceived value of IV-style therapies with the flexibility, convenience, and sustainability of at-home use, without sacrificing clinical oversight or quality standards.
